| Literature DB >> 35784589 |
Olukayode Olugbenga Orole1, Salihu Moses Gambo1, Victor Stephen Fadayomi2.
Abstract
The spread and transfer of resistant pathogens is on the increase worldwide and it is presently a cause of concern for health facilities, health organizations and governments. Pathogenicity is a factor dependent on the virulence of the microorganisms. The study aimed at determining the virulence markers and factors in multidrug resistant (MDR) Escherichia coli isolated from patients with urinary tract and gastrointestinal tract infections in Lafia, Nigeria. Collection of urine and stool samples (150 each) from patients was carried out, and bacteria isolated from the samples using the spread plate technique. Antibiotic susceptibility test was determined to identify resistant E. coli isolates after which, virulence factors and genes conferring virulence evaluated. The prevalence of E. coli was 33.3% and 35.3% in urine and stool respectively with 42 of the isolates being MDR. All the isolates showed cell surface hydrophobicity on ammonia sulfate molarity at >1.5, and all possessed capacity to produce hemolysin and pyrogen, though isolate U6 produced the highest amount of hemolysin and the other isolates mostly produced reasonable amount of pyrogen. Isolate U19 from urine sample and isolates S6, S10, S11, and S17 from stool samples all had between 81 and 100 serum resistance survival percentages, while 13 of the isolates had no serum resistance capabilities. Virulence conferring genes present in the isolates include fimH, pap, stb, cs31a, vt2, east1. Most of the resistant isolates have more than one virulence marker that is a means of producing an effective pathogenesis.Entities:
Keywords: Antibiotics; bacteria; pathogenesis; resistance; virulence
Year: 2022 PMID: 35784589 PMCID: PMC9247993 DOI: 10.1177/11786361221106993
Source DB: PubMed Journal: Microbiol Insights ISSN: 1178-6361
Primer sequences for the virulence markers checked.
| Gene | Sequence (5′-3′) | Amplicon (bp) | Reference | |
|---|---|---|---|---|
| Colonization factors | ||||
| | Type I fimbriae | TGCAGAACGGATAAGCCGTGG | 508 | Johnson and Stell
|
| GCAGTCACCTGCCCTCCGGTA | ||||
| | Coli surface associated | GGGCGCTCTCTCCTTCAAC | 402 | Bertin et al
|
| CGCCCTAATTGCTGGCGAC | ||||
| | Intimin | GACCCGGCACAAGCATAAGC | 384 | Yu and Kaper
|
| CCACCTGCAGCAACAAGAGG | ||||
| Toxins | ||||
| | Heat-stable enterotoxin b | ATCGCATTTCTTCTTGCATC | 172 | Blanco et al
|
| GGGCGCCAAAGCATGCTCC | ||||
| | Verotoxin II | GGGCAGTTATTTTGCTGTGGA | 386 | Ojeniyi et al
|
| GTATCTGCCTGAAGCGTAA | ||||
Cell surface hydrophobicity of isolates from urinary and gastrointestinal tracts.
| Salt aggregation | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ammonium sulfate molarity (M) | |||||||||||
| 0.01 | 0.03 | 0.06 | 0.1 | 0.2 | 0.4 | 0.5 | 1.0 | 1.3 | 1.5 | >1.5 | |
| S1, S16, U15 | − | − | − | + | + | + | + | + | + | + | + |
| S2 | − | − | − | − | − | + | + | + | + | + | + |
| S5, S22, U7, U19 | − | + | + | + | + | + | + | + | + | + | + |
| S12, U20 | − | − | − | − | − | − | − | − | − | + | + |
| S20 | − | − | − | − | − | − | − | + | + | + | + |
| S3, S4, S7, S8, S9, S13, S14, S18, S19, S21, U1, U4, U5, U6, U8, U9, U13, U14, U16, U17, U18 | − | − | − | − | − | − | − | − | − | − | + |
| S6, S10, S11,S15, S17, U2, U3, U10, U11, U12 | + | + | + | + | + | + | + | + | + | + | + |
S, resistant Escherichia coli isolates from gastrointestinal tract; U, resistant Escherichia coli isolates from urinary tract; +, positive; −, negative.
Serum resistance potential of resistant E. coli isolates.
| Percentage survival | Urine sample | Fecal sample | ||
|---|---|---|---|---|
| Isolates | No of isolates (%) | Isolates | No of isolates (%) | |
| n = 20 | n = 22 | |||
| 0 | U1,U4,U5,U13,U14 | 5 (25.00) | S2,S5,S12,S13,S15,S16,S20,S21 | 8 (36.36) |
| 1-20 | U2,U3,U7,U8,U16,U17 | 6 (30.00) | S3,S4,S7,S19 | 4 (18.18) |
| 21-40 | U18,U20 | 2 (10.00) | S8,S9,S14 | 3 (13.63) |
| 41-60 | U9,U11,U12 | 3 (15.00) | S18 | 1 (4.54) |
| 61-80 | U6,U10,U15 | 3 (15.00) | S1,S22 | 2 (9.09) |
| 81-100 | U19 | 1 (5.00) | S6,S10,S11,S17 | 4 (18.18) |
Production of virulence factors and the antibiotic resistance profile of E. coli isolates.
| S/N | Alpha hemolysin | Pyrogen detection | Antibiotic resisted | |
|---|---|---|---|---|
| 1 | S1 | - | ++ | CTX, IMP, SXT, CIP |
| 2 | S2 | - | +++ | CTX, CN, SXT, CAZ |
| 3 | S3 | x | + | CRO, IMP, SXT, CN |
| 4 | S4 | - | + | CRO, IMP, SXT |
| 5 | S5 | - | ++ | AMP, CIP, CRO, SXT |
| 6 | S6 | - | +++ | AMP, AMC, IMP, STR |
| 7 | S7 | - | +++ | AMP, CIP, CTX, CRO |
| 8 | S8 | - | +++ | AMP, AMC, STR, CAZ, SXT |
| 9 | S9 | - | ++ | AMP, CN, IMP, SXT |
| 10 | S10 | - | + | AMP, AMC, CIP, CRO, CAZ |
| 11 | S11 | - | ++ | AMP, AMCCIP, CTX |
| 12 | S12 | - | ++ | AMP, STR, SXT, CRO |
| 13 | S13 | - | +++ | AMP, AMC, SXT, CAZ |
| 14 | S14 | x | ++ | CRO, CN, STR, SXT |
| 15 | S15 | - | +++ | AMP, CN, SXT, CTX |
| 16 | S16 | - | +++ | AMP, AMC, STR, SXT |
| 17 | S17 | - | +++ | AMP, STR, CAZ, CRO |
| 18 | S18 | - | ++ | AMP, AMC, SXT, CN |
| 19 | S19 | - | ++ | AMP, STR, CTX, SXT |
| 20 | S20 | - | +++ | SXT, CIP, CAZ, STR |
| 21 | S21 | - | + | AMC, STR, CTX, CN |
| 22 | S22 | - | +++ | AMP, AMC, STR, SXT, CRO |
| 23 | U1 | x | +++ | AMP, AMC, CIP, IMP, CRO |
| 24 | U2 | - | +++ | AMP, AMC, CN, SXT, CTX |
| 25 | U3 | - | +++ | AMP, AMC, CAZ, CRO, SXT, CIP, STR, CT |
| 26 | U4 | - | ++ | AMP, CN, SXT, CTX, IMP |
| 27 | U5 | - | +++ | AMP, STR, CAZ, CN, CIP |
| 28 | U6 | x | +++ | AMP, STR, CTX, SXT, CN |
| 29 | U7 | - | +++ | SXT, CIP, CAZ, STR, CN |
| 30 | U8 | x | + | AMC, CTX, CN, SXT, CAZ |
| 31 | U9 | x | ++ | AMP, AMC, STR, SXT, CN |
| 32 | U10 | x | +++ | AMP, CIP, IMP, SXT, CN |
| 33 | U11 | - | ++ | AMP, AMC, CN, SXT, CTX, CAZ |
| 34 | U12 | - | ++ | AMP, CAZ, SXT, CIP, STR, CTX, CN |
| 35 | U13 | - | ++ | AMP, STR, CTX, SXT, CN |
| 36 | U14 | x | +++ | SXT, CIP, CAZ, STR, CN |
| 37 | U15 | - | + | AMC, CTX, CN, SXT, CAZ |
| 38 | U16 | - | +++ | AMP, AMC, STR, SXT, CN |
| 39 | U17 | - | ++ | AMP, CIP, IMP, SXT, CN |
| 40 | U18 | - | ++ | AMP, AMC, CN, SXT, CTX, CAZ |
| 41 | U19 | x | +++ | AMP, CAZ, SXT, CIP, STR, CTX, CN |
| 42 | U20 | x | +++ | AMP, AMC, CIP, CAZ, CN, STR, SXT, CTX |
x, hemolysin producer; -, non-hemolysin producer; +++, very deep color change; ++, deep color change; +, low intensity color change; S, resistant Escherichia coli isolates from gastrointestinal tract; U, resistant Escherichia coli isolates from urinary tract; IPM, imipenems; CIP, ciprofloxacin; CAZ, ceftazidine; CN, gentamycin; CTX, cefotaxime; CRO, ceftriaxone; STR, streptomycin; SXT, sulphamethoxazole/trimethoprim; AMC, amoxycillin/clavulanic acid; AMP, ampicillin.
Prevalence of genes encoding virulence markers in Escherichia coli isolates.
| Virulence markers | No. of isolates | Isolates |
|---|---|---|
|
| 23 | S2, S5, S7, S8, S11, S14, S17, S19, S21, U1, U2, U3, U4, U5, U6, U7, U9, U12, U13, U15, U16, U17, U20 |
|
| 4 | S5, S11, S14, U6 |
|
| 3 | S8, U2, U13 |
|
| 3 | U5, U7, U20 |
|
| 1 | U9 |
|
| 3 | S19, S21, U1, U7, U13 |
| Total | 36 |
S, isolates from gastrointestinal tract; U, isolates from urinary tract.